Literature DB >> 24484653

Nontuberculous mycobacterial (NTM) lung disease: the top ten essentials.

Timothy R Aksamit1, Julie V Philley2, David E Griffith3.   

Abstract

This review will utilize essential questions about nontuberculous mycobacterial (NTM) lung disease to succinctly address important new developments in the pathogenesis, diagnosis and management of NTM lung disease with a focus on practical information and "bottom line" answers. 1) What do I tell my patients who ask, “where did I get this infection” and, “should I take showers”? 2) What is the connection between bronchiectasis and the acquisition of NTM lung infection? 3) What other factors are important in the pathogenesis of NTM lung disease? 4) Why does it seem that am I seeing more new NTM lung disease patients? 5) Why is the diagnosis of NTM lung disease so complicated and does the diagnosis of NTM lung infection obligate specific treatment? 6) Unlike traditional tuberculosis, what is behind the irrelevance of most in vitro susceptibility testing reports for NTM infections? 7) Is there anything new for the management of patients with Mycobacterium avium complex lung disease? How does the radiographic appearance influence treatment? 8) Is there anything new for the management of patients with Mycobacterium abscessus lung disease? 9) What about the management of other NTM respiratory pathogens? 10) Is there a role for the use of macrolide monotherapy for non-cystic fibrosis bronchiectasis?
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Mycobacterium abscessus; Mycobacterium avium Complex (MAC); Nontuberculous mycobacteria

Mesh:

Substances:

Year:  2013        PMID: 24484653     DOI: 10.1016/j.rmed.2013.09.014

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  43 in total

Review 1.  New antituberculous drugs derived from natural products: current perspectives and issues in antituberculous drug development.

Authors:  Masayuki Igarashi; Yoshimasa Ishizaki; Yoshiaki Takahashi
Journal:  J Antibiot (Tokyo)       Date:  2017-11-01       Impact factor: 2.649

2.  Diffuse bronchiectasis and airflow obstruction in granulomatosis with polyangiitis.

Authors:  T Barba; C Khouatra; J Traclet J; J F Cordier; V Cottin
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2018-04-28       Impact factor: 0.670

Review 3.  Gender susceptibility to mycobacterial infections in patients with non-CF bronchiectasis.

Authors:  Mehdi Mirsaeidi; Ruxana T Sadikot
Journal:  Int J Mycobacteriol       Date:  2015-06

4.  Response to Switch from Intermittent Therapy to Daily Therapy for Refractory Nodular Bronchiectatic Mycobacterium avium Complex Lung Disease.

Authors:  Won-Jung Koh; Byeong-Ho Jeong; Kyeongman Jeon; Hye Yun Park; Su-Young Kim; Hee Jae Huh; Chang-Seok Ki; Nam Yong Lee; Sung Jae Shin; Charles L Daley
Journal:  Antimicrob Agents Chemother       Date:  2015-05-18       Impact factor: 5.191

5.  Performance of a Highly Sensitive Mycobacterium tuberculosis Complex Real-Time PCR Assay for Diagnosis of Pulmonary Tuberculosis in a Low-Prevalence Setting: a Prospective Intervention Study.

Authors:  Víctor Vinuesa; Rafael Borrás; María Luisa Briones; María Ángeles Clari; Vicenta Cresencio; Estela Giménez; Carmen Muñoz; Rosa Oltra; Emilio Servera; Talia Scheelje; Carlos Tornero; David Navarro
Journal:  J Clin Microbiol       Date:  2018-04-25       Impact factor: 5.948

Review 6.  Practice Guidelines for Clinical Microbiology Laboratories: Mycobacteria.

Authors:  Betty A Forbes; Geraldine S Hall; Melissa B Miller; Susan M Novak; Marie-Claire Rowlinson; Max Salfinger; Akos Somoskövi; David M Warshauer; Michael L Wilson
Journal:  Clin Microbiol Rev       Date:  2018-01-31       Impact factor: 26.132

7.  Screening of Preselected Libraries Targeting Mycobacterium abscessus for Drug Discovery.

Authors:  Adrian Richter; Angelika Strauch; Joseph Chao; Mary Ko; Yossef Av-Gay
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

8.  In Vitro MIC Values of Rifampin and Ethambutol and Treatment Outcome in Mycobacterium avium Complex Lung Disease.

Authors:  Yong Pil Chong; Kyung-Wook Jo; Byoung Soo Kwon; Mi-Na Kim; Heungsup Sung; Younsuck Koh; Woo-Sung Kim; Jin-Woo Song; Yeon-Mok Oh; Sang-Do Lee; Sei Won Lee; Jae-Seung Lee; Chae-Man Lim; Chang-Min Choi; Jin-Won Huh; Sang-Bum Hong; Sojung Park; Tae Sun Shim
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

9.  Modern Healthcare Versus Nontuberculous Mycobacteria: Who Will Have the Upper Hand?

Authors:  Matthew B Crist; Joseph F Perz
Journal:  Clin Infect Dis       Date:  2017-04-01       Impact factor: 9.079

10.  Symptom Burden and Medication Use Among Patients with Nontuberculous Mycobacterial Lung Disease.

Authors:  Vira Pravosud; David M Mannino; Delia Prieto; Quan Zhang; Radmila Choate; Elisha Malanga; Timothy R Aksamit
Journal:  Chronic Obstr Pulm Dis       Date:  2021-04-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.